Tag Archives: Sanofi Aventis

Novartis takes total control of Alcon

In a $28Bn USD operation, the Swiss Pharmaceutical buys the 52% of Alcon’s remanent stock from Nestlé. Novartis would own an approximate 77 percent interest in Alcon. The operation goes at least one and a half year earlier than estimated in … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud | Tagged , , , , , , , , , , , , , , | Leave a comment

AH1N1 Flu, Kimberly-Clark and the “Condom Effect”

By Xavier Tello The current AH1N1 Flu pandemic has unexpectedly brought benefits to some companies; and we are not talking about Tamiflu’s manufacturer Roche or Influenza Vaccine experts such as Glaxo or sanofi-aventis. Last July 23rd, Kimberly-Clark Corporation announced its … Continue reading

Posted in Alta Dirección, Mercadotecnia, Opinión, Ventas | Tagged , , , , , , , , , , , , , , , , , , | 1 Comment

Influenza A(H1N1). La OMS pide a Sanofi Pasteur desarrollar una vacuna / Sanofi Pasteur contacted by WHO for vaccine development

ENGLISH BELOW Sanofi Pasteur ha dicho este miércoles que “se encuentra listo para desarrollar una vacuna contra el A(H1N1) identificado por la OMS“, según un anota publicada en Les Echos. De acuerdo con este influyente diario, la OMS ya ha contactado al laboratorio Francés … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , | 2 Comments

FDA Advisory Committee Briefing hits Bayer’s Xarelto® badly.

By Xavier Tello One of the most desired markets of the pharmaceutical business has been the clotting-prevention. Ever since the first use of systemic heparin and the late surging of the low molecular weight heparins (LMWH) such as Lovenox® (enoxaparin), … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Sanofi-Aventis shows 2008 figures and new Top Executive Positions.

Written by Xavier Tello This morning sanofi-aventis has released to the press its financial results for 2008. The results, conservative (as expected) but “above guidance” are shown bellow.   Key comments: 2008 Net Sales: € 27,568 M (+ 3.7%) EPS at €5.49 … Continue reading

Posted in Alta Dirección, Mercadotecnia, Planeac. Estratégica, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment